MENU
Aim higher

ANTITHAB

A new therapeutic approach for severe bleeding

To develop a new treatment of severe bleeding to be used as prophylaxis or on demand. This innovative treatment, given systemically, prolongs the half-life of activated clotting factors at the site(s) of injury by neutralizing the main inhibitor of clotting in the blood, antithrombin III (AT). We will deliver 1) a humanized monoclonal antibody inhibiting AT; 2) cell lines producing the antibody; and 3) proof of concept for efficacy of the antibody in an animal model for severe bleeding.
Acronym: 
ANTITHAB
Project ID: 
9 763
Ranking: 
79
Cut-off: 
3
Start date: 
01-07-2015
Project Duration: 
42months
Project costs: 
1 553 990.00€
Technological Area: 
Biochemistry / Biophysics
Market Area: 
Monoclonal Antibodies and Hybridomas